Gain Therapeutics (GANX) Return on Invested Capital (2021 - 2026)

Gain Therapeutics' Return on Invested Capital history runs 6 years deep, the most recent figure standing at 0.34% for Q1 2026.

• In Q1 2026, Return on Invested Capital rose 12.0% year-over-year to 0.34%; the TTM figure through Mar 2026 stood at 0.34% (up 12.0% YoY), while the FY2025 annual figure was 1.4%, up 42.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.34%, down from 0.31% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.31% in Q4 2025, with the low at 0.75% in Q4 2022.
• The 5-year median for Return on Invested Capital is 0.46% (2025), against an average of 0.47%.
• Peak annual rise in Return on Invested Capital reached 76 bps in 2022, while the deepest fall reached 22 bps in 2022.
• Gain Therapeutics' Return on Invested Capital stood at 0.75% in 2022, then soared by 33 bps to 0.5% in 2023, then grew by 9 bps to 0.46% in 2024, then soared by 32 bps to 0.31% in 2025, then retreated by 10 bps to 0.34% in 2026.
• Business Quant data shows GANX's Return on Invested Capital at 0.34% in Q1 2026, 0.31% in Q4 2025, and 0.4% in Q3 2025.